Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Karama Asleh
  • Stina Lyck Carstensen
  • Charlotte L Tykjaer Jørgensen
  • Samantha Burugu
  • Dongxia Gao
  • Jennifer R Won
  • Maj-Britt Jensen
  • Eva Balslev
  • Anne-Vibeke Laenkholm
  • Dorte L Nielsen
  • Bent Ejlertsen
  • Torsten O Nielsen
Vis graf over relationer

In a formal prospective-retrospective analysis of the phase III SBG0102 clinical trial randomizing metastatic breast cancer patients to gemcitabine-docetaxel or to single agent docetaxel, patients with basal-like tumors by PAM50 gene expression had significantly better overall survival in the gemcitabine arm. By immunohistochemistry (IHC), triple negative status was not predictive, but more specific biomarkers have since become available defining basal-like by nestin positivity or loss of inositol-polyphosphate-4-phosphate (INPP4B). Here, we evaluate their capacity to identify which patients benefit from gemcitabine in the metastatic setting. Nestin and INPP4B staining and interpretation followed published methods. A prespecified statistical plan evaluated the primary hypothesis that patients with basal-like breast cancer, defined as "nestin+ or INPP4B-", would have superior overall survival on gemcitabine-docetaxel when compared to docetaxel. Interaction tests, Kaplan-Meier curves and forest plots were used to assess prognostic and predictive capacities of biomarkers relative to treatment. Among 239 cases evaluable for our study, 36 (15%) had been classified as basal-like by PAM50. "Nestin+ or INPP4B-" was observed in 41 (17%) of the total cases and was significantly associated with PAM50 basal-like subtype. Within an estimated median follow-up of 13 years, patients assigned as IHC basal "nestin+ or INPP4B-" had significantly better overall survival on gemcitabine-docetaxel versus docetaxel monotherapy (HR = 0.31, 95%CI: 0.16-0.60), whereas no differences were observed for other patients (HR = 0.99), p-interaction<0.01. In the metastatic setting, women with IHC basal breast cancers defined as "nestin+ or INPP4B-" have superior overall survival when randomized to gemcitabine-containing chemotherapy compared to docetaxel alone. These findings need to be validated using larger prospective-retrospective phase III clinical trials series.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind144
Udgave nummer10
Sider (fra-til)2578-2586
Antal sider9
ISSN0020-7136
DOI
StatusUdgivet - 2019

ID: 55905373